Federal Register / Vol. 72, No. 63 / Tuesday, April 3, 2007 / Notices 15889 

and other device-oriented information. 

The CDRH Web site may be accessed at 

http://www.fda.gov/cdrh. A search 

capability for all CDRH guidance 

documents is available at http:// 

www.fda.gov/cdrh/guidance.html. 

Guidance documents are also available 

on the Division of Dockets Management 

Internet site at http://www.fda.gov/ 

ohrms/dockets. 

IV. Paperwork Reduction Act of 1995 

This guidance refers to previously 

approved collections of information 

found in FDA regulations. These 

collections of information are subject to 

review by the Office of Management and 

Budget (OMB) under the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501–

3520). The collections of information in 

21 CFR part 807 subpart E have been 

approved under OMB Control No. 0910–

0120; and the collections of information 

in 21 CFR part 801 and 21 CFR 809.10 

have been approved under OMB Control 

No. 0910–0485. 

V. Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic 

comments regarding this document. 

Submit a single copy of electronic 

comments or two paper copies of any 

mailed comments, except that 

individuals may submit one paper copy. 

Comments are to be identified with the 

docket number found in brackets in the 

heading of this document. The guidance 

and received comments may be seen in 

the Division of Dockets Management 

between 9 a.m. and 4 p.m., Monday 

through Friday. 

Dated: March 23, 2007. 

Linda S. Kahan, 

Deputy Director, Center for Devices and 

Radiological Health. 

[FR Doc. E7–6168 Filed 4–2–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Proposed Collection: 

Comment Request 

In compliance with the requirement 

for opportunity for public comment on 

proposed data collection projects 

(section 3506(c)(2)(A) of Title 44, United 

States Code, as amended by the 

Paperwork Reduction Act of 1995, 

Public Law 104–13), the Health 

Resources and Services Administration 

(HRSA) publishes periodic summaries 

of proposed projects being developed 

for submission to the Office of 

Management and Budget (OMB) under 

the Paperwork Reduction Act of 1995. 

To request more information on the 

proposed project or to obtain a copy of 

the data collection plans and draft 

instruments, call the HRSA Reports 

Clearance Officer on (301) 443–1129. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. 

Proposed Project: Federally Qualified 

Health Centers (FQHC) Application 

Forms: (OMB No. 0915–0285 Revision) 

HRSA’s Bureau of Primary Health 

Care (BPHC) FQHCs are a major 

component of America’s health care 

safety net, the Nation’s ‘‘system’’ of 

providing health care to low-income 

and other vulnerable populations. 

Health centers care for people regardless 

of their ability to pay and whether or 

not they have health insurance. They 

provide primary and preventive health 

care, as well as services such as 

transportation and translation. Many 

health centers also offer dental, mental 

health, and substance abuse care. 

FQHCs are administered by HRSA’s 

BPHC. 

HRSA uses the following application 

forms to administer and manage FQHCs. 

These application forms are used by 

new and existing FQHCs to apply for 

grant and non-grant opportunities, renew their grant or non-grant 

opportunities, or change their scope of 

project. 

Estimated of annualized reporting 

burden are as follows: 

Type of application form 

Number of 

respondents 

Responses 

per respondent 

Total number of responses 

Hours per 

response 

Total burden hours 

General Information Worksheet ......................................................................... 1,021 1 1,021 3.0 3,063 

P12 Planning General Information Worksheet .................................................. 300 1 300 12.0 3,600 

BPHC Funding Request Summary .................................................................... 1,021 1 1,021 0.5 510 

Institutional File Assurances .............................................................................. 1,021 1 1,021 0.5 510 

Proposed Staff Profile ........................................................................................ 1,021 1 1,021 6.0 6,126 

Income Analysis Form ....................................................................................... 1,021 1 1,021 15.0 15,315 

Community Characteristics ................................................................................ 1,021 1 1,021 12.0 12,252 

Services Provided .............................................................................................. 1,021 1 1,021 0.5 510 

Sites Listing ........................................................................................................ 1,021 1 1,021 1.0 1,021 

Other Site Activities ........................................................................................... 700 1 700 0.5 350 

Board Member Characteristics .......................................................................... 1,021 1 1,021 1.0 1,021 

Request for Waiver of Governance Requirements ........................................... 150 1 150 1.0 150 

Compliance Matrix ............................................................................................. 1,021 1 1,021 0.5 510 

Health Center Affiliation Certification ................................................................. 250 1 250 0.5 125 

Need for Assistance ........................................................................................... 900 1 900 6.0 5,400 

Emergency Preparedness Form ........................................................................ 1,021 1 1,021 1.0 1,021 

FTCA Form ........................................................................................................ 800 1 800 1.0 800 

Points of Contact ............................................................................................... 800 1 800 0.5 400 

Total ............................................................................................................ 15,131 .................. 15,131 .................. 52,684 

Send comments to Susan G. Queen, 

Ph.D., HRSA Reports Clearance Officer, 

Room 14–33, Parklawn Building, 5600 

Fishers Lane, Rockville, MD 20857. 

Written comments should be received 

within 60 days of this notice. 


ycherry on PROD1PC64 with NOTICES
15890 Federal Register / Vol. 72, No. 63 / Tuesday, April 3, 2007 / Notices 

Dated: March 27, 2007. 

Alexandra Huttinger, 

Acting Director, Division of Policy Review 

and Coordination. 

[FR Doc. E7–6089 Filed 4–2–07; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the laboratories currently 

certified to meet the standards of 

Subpart C of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908), 

on September 30, 1997 (62 FR 51118), 

and on April 13, 2004 (69 FR 19644). 

A notice listing all currently certified 

laboratories is published in the Federal 

Register during the first week of each 

month. If any laboratory’s certification 

is suspended or revoked, the laboratory 

will be omitted from subsequent lists 

until such time as it is restored to full 

certification under the Mandatory 

Guidelines. 

If any laboratory has withdrawn from 

the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end, 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://workplace.samhsa.gov 

and http://www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh or Dr. Walter Vogl, 

Division of Workplace Programs, 

SAMHSA/CSAP, Room 2–1035, 1 Choke 

Cherry Road, Rockville, Maryland 

20857; 240–276–2600 (voice), 240–276–

2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were developed 

in accordance with Executive Order 

12564 and section 503 of Public Law 

100–71. Subpart C of the Mandatory 

Guidelines, ‘‘Certification of 

Laboratories Engaged in Urine Drug 

Testing for Federal Agencies,’’ sets strict 

standards that laboratories must meet in 

order to conduct drug and specimen 

validity tests on urine specimens for 

Federal agencies. To become certified, 

an applicant laboratory must undergo 

three rounds of performance testing plus 

an on-site inspection. To maintain that 

certification, a laboratory must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories which claim to be in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A laboratory 

must have its letter of certification from 

HHS/SAMHSA (formerly: HHS/NIDA) 

which attests that it has met minimum 

standards. 

In accordance with Subpart C of the 

Mandatory Guidelines dated April 13, 

2004 (69 FR 19644), the following 

laboratories meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328–

7840/800–877–7016, (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290–

1150. 

Aegis Analytical Laboratories, Inc., 345 

Hill Ave., Nashville, TN 37210, 615–

255–2400. 

Baptist Medical Center-Toxicology 

Laboratory, 9601 I–630, Exit 7, Little 

Rock, AR 72205–7299, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800–

445–6917. 

Diagnostic Services, Inc., dba DSI, 

12700 Westlinks Drive, Fort Myers, 

FL 33913, 239–561–8200/800–735–

5416. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671–

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

Dynacare Kasper Medical Laboratories,*

10150–102 St., Suite 200, Edmonton, 

Alberta, Canada T5J 5E2, 780–451–

3702/800–661–9876. 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662–

236–2609. 

Gamma-Dynacare Medical 

Laboratories,* A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519–

679–1630. 

Kroll Laboratory Specialists, Inc., 1111 

Newton St., Gretna, LA 70053, 504–

361–8989/800–433–3823, (Formerly: 

Laboratory Specialists, Inc.). 

Kroll Scientific Testing Laboratories, 

Inc., 450 Southlake Blvd., Richmond, 

VA 23236, 804–378–9130, (Formerly: 

Scientific Testing Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984. 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 10788 Roselle St., San 

Diego, CA 92121, 800–882–7272, 

(Formerly: Poisonlab, Inc.). 

Laboratory Corporation of America 

Holdings, 550 17th Ave., Suite 300, 

Seattle, WA 98122, 206–923–7020/ 

800–898–0180. (Formerly: DrugProof, 

Division of Dynacare/Laboratory of 

Pathology, LLC; Laboratory of 

Pathology of Seattle, Inc.; DrugProof, 

Division of Laboratory of Pathology of 

Seattle, Inc.). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.). 

Marshfield Laboratories, Forensic 

Toxicology Laboratory, 1000 North 

Oak Ave., Marshfield, WI 54449, 715–

389–3734/800–331–3734. 

MAXXAM Analytics Inc.,* 6740 

Campobello Road, Mississauga, ON, 

Canada L5N 2L8, 905–817–5700, 

(Formerly: NOVAMANN (Ontario), 

Inc.). 


ycherry on PROD1PC64 with NOTICES